Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease.

Neuropsychiatric Disease and Treatment
William J McGeownAnnalena Venneri

Abstract

Neuroimaging studies of cholinesterase inhibitor (ChEI) treatment in Alzheimer's disease (AD) indicate that the short and long term actions of ChEIs are dissimilar. fMRI studies of the ChEI rivastigmine have focused on its short term action. In this exploratory study the effect of prolonged (20 weeks) rivastigmine treatment on regional brain activity was measured with fMRI in patients with mild AD. Eleven patients with probable AD and nine age-matched controls were assessed with a Pyramids and Palm Trees semantic association and an n-back working memory fMRI paradigm. In the patient group only, the assessment was repeated after 20 weeks of treatment. There was an increase in task-related brain activity after treatment with activations more like those of normal healthy elderly. Behaviorally, however, there were no significant differences between baseline and retest scores, with a range of performance probably reflecting variation in drug efficacy across patients. Variable patient response and drug dynamic/kinetic factors in small patient groups will inevitably bias (either way) the effect size of any relevant drug related changes in activation. Future studies should take drug response into account to provide more insight into th...Continue Reading

References

Sep 1, 1975·Archives of Neurology·V C HachinskiL Symon
Sep 19, 1996·Nature·R VandenbergheR S Frackowiak
Jan 1, 1997·International Psychogeriatrics·R C PetersenE G Tangelos
Dec 17, 1998·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·S M CourtneyL G Ungerleider
Oct 18, 2000·The Cochrane Database of Systematic Reviews·J S BirksH Beppu
Oct 17, 2001·The International Journal of Neuropsychopharmacology·S G PotkinJ H Fallon
Jul 26, 2002·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Flavio NobiliGuido Rodriguez
Nov 20, 2002·Journal of Neurology, Neurosurgery, and Psychiatry·S A R B RomboutsP Scheltens
Feb 22, 2003·NeuroImage·Dick J VeltmanRaymond J Dolan
May 14, 2004·Brain : a Journal of Neurology·Andrew J SaykinRobert B Santulli
Nov 5, 2004·The European Journal of Neuroscience·R R DaviesJohn R Hodges
May 17, 2005·NeuroImage·D S SabsevitzJ R Binder
Nov 16, 2005·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Tilo T J KircherDirk T Leube
Feb 18, 2006·Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging·Soichiro ShimizuKimihiko Abe
Apr 11, 2006·Cerebral Cortex·Mathieu VandenbulckeRik Vandenberghe
Oct 27, 2006·Journal of the International Neuropsychological Society : JINS·Juliana V BaldoNina F Dronkers
Apr 20, 2007·Magnetic Resonance Imaging·Michael F ShanksAnnalena Venneri
Apr 21, 2007·Magnetic Resonance Imaging·Annalena Venneri

❮ Previous
Next ❯

Software Mentioned

Talairach Daemon Client
Presentation
SPM
SPM2
Statistical Parametric Mapping ( SPM2 )

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.